{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Tarone L"],"funding":["Italian Ministry of Health","University of Turin","Fondazione Umberto Veronesi","Fondazione Compagnia di San Paolo","Italian foundation for cancer research (FIRC)","Fondazione Ricerca Molinette Onlus"],"pagination":["2099"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9783386"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(12)"],"pubmed_abstract":["Osteosarcoma (OSA) is the most common pediatric malignant bone tumor. Although surgery together with neoadjuvant/adjuvant chemotherapy has improved survival for localized OSA, most patients develop recurrent/metastatic disease with a dismally poor outcome. Therapeutic options have not improved for these OSA patients in recent decades. As OSA is a rare and \"orphan\" tumor, with no distinct targetable driver antigens, the development of new efficient therapies is still an unmet and challenging clinical need. Appropriate animal models are therefore critical for advancement in the field. Despite the undoubted relevance of pre-clinical mouse models in cancer research, they present some intrinsic limitations that may be responsible for the low translational success of novel therapies from the pre"],"journal":["Life (Basel, Switzerland)"],"pubmed_title":["Improving Osteosarcoma Treatment: Comparative Oncology in Action."],"pmcid":["PMC9783386"],"funding_grant_id":["RILO 2022","RF2013-02359216","4298","PoC-INSTRUMENT D17H21000640007","RILO 2020","16548","8893/5"],"pubmed_authors":["Buracco P","Mareschi K","Morello E","Camerino M","Cavallo F","Riccardo F","Tarone L","Tirtei E","Giacobino D"],"additional_accession":[]},"is_claimable":false,"name":"Improving Osteosarcoma Treatment: Comparative Oncology in Action.","description":"Osteosarcoma (OSA) is the most common pediatric malignant bone tumor. Although surgery together with neoadjuvant/adjuvant chemotherapy has improved survival for localized OSA, most patients develop recurrent/metastatic disease with a dismally poor outcome. Therapeutic options have not improved for these OSA patients in recent decades. As OSA is a rare and \"orphan\" tumor, with no distinct targetable driver antigens, the development of new efficient therapies is still an unmet and challenging clinical need. Appropriate animal models are therefore critical for advancement in the field. Despite the undoubted relevance of pre-clinical mouse models in cancer research, they present some intrinsic limitations that may be responsible for the low translational success of novel therapies from the pre","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2025-04-21T14:16:34.615Z","creation":"2025-02-19T03:01:14.653Z"},"accession":"S-EPMC9783386","cross_references":{"pubmed":["36556464"],"doi":["10.3390/life12122099"]}}